3 days ago · Evergreen is a clinical-stage radiopharmaceutical company engaged in Contract Development and Manufacturing (CDMO) services as well as drug discovery and …

1 day ago · US-based radiopharmaceutical company Lantheus has announced a definitive agreement to acquire clinical-stage radiopharma contract development and manufacturing …

1 day ago · Lantheus is acquiring radiopharmaceutical CDMO Evergreen Theragnostics in a deal worth up to $1 billion, expanding its manufacturing capabilities and drug pipeline. The …

2 days ago · Under the terms of the agreement, Lantheus will pay an upfront amount of $250 million in cash at closing and up to $752.5 million in development and sales milestones related …

2 days ago · Lantheus has reached an agreement to acquire radiopharmaceutical firm Evergreen Theragnostics for up to $1 billion, the two announced Tuesday. Founded in 2019 and …

2 days ago · On Tuesday, Lantheus Holdings, Inc. (NASDAQ:LNTH) agreed to acquire Evergreen Theragnostics, Inc. in an all-cash transaction involving an upfront payment of $250 million and …

3 days ago · Lantheus (LNTH) announced a definitive agreement to acquire Evergreen Theragnostics in an all-cash transaction consisting of an upfront payment of $250M and up to …

3 days ago · Evergreen’s ability to work with a variety of diagnostic and therapeutic isotopes will enhance Lantheus’ ability to address the complexities of radiopharmaceutical development …

2 days ago · Lantheus Holdings is stepping up its game in the radiopharmaceutical space by acquiring Massachusetts-based Evergreen Theragnostics for $250 million upfront. As part of …

2 days ago · Lantheus Holdings Inc. is adding to its portfolio yet again, acquiring a clinical-stage radiopharmaceutical company in a deal worth up to about $1 billion.